Clinical Trials Logo

Rectal Cancer, Adenocarcinoma clinical trials

View clinical trials related to Rectal Cancer, Adenocarcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05286086 Not yet recruiting - Chemoradiotherapy Clinical Trials

Prehabilitation in Rectal Cancer: During Neoadjuvant Therapy vs Preoperative

PREHAREC
Start date: March 2022
Phase: N/A
Study type: Interventional

Control of the effect of prehabilitation on postoperative morbidity, assessed by the Comprehensive Complication Index (CCI), in patients diagnosed with rectal cancer that will receive neoadjuvant Quimiorradiotherapy (NCRT) and subsequent surgery, performed at the beginning of NCRT or before surgery.

NCT ID: NCT03042000 Not yet recruiting - Clinical trials for Rectal Cancer, Adenocarcinoma

Multicenter, Prospective, RCT:Investigation of Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer.

Start date: February 2017
Phase: N/A
Study type: Interventional

At present, the combined modality treatment of preoperative neoadjuvant chemoradiotherapy (NCRT) followed by radical surgery has become the standard of care for the locally advanced mid/low rectal cancer, having been proved to substantially improve the local control of the disease, whereas not being able to improve the long-term survival. According to present clinical practice guidelines, all patients with cT3-4N0M0 or cTanyN1-2M0 mid/low rectal cancer are recommended to undergo the preoperative long-term radiotherapy with concurrent 5FU based chemotherapy, followed by the radical resection of the tumor. After surgery, adjuvant chemotherapy (ACT) is recommended for all these patients without considering the postoperative pathological results. Recently, however, some authors proposed that different strategy of combined modality therapy should be applied in different patients according to their risk of relapse, instead of using the uniform NCRT strategy. In this research, on the basis of investigator's previous clinical practice and researches, investigators plan to stratify the patients with cT3-4N0M0 or cTanyN1-2M0 mid/low rectal cancer into several subgroups according to tumor stages and the risk of relapse. Different therapeutic strategy will be applied in different groups, at the aim of improving the overall therapeutic effects, as well as reducing the treatment adverse effects. This research consists of four trials.

NCT ID: NCT03038217 Not yet recruiting - Clinical trials for Rectal Cancer, Adenocarcinoma

Investigation of the Value of ctDNA in Diagnosis, Treatment, and Surveillance of Surgically Resectable Colorectal Cancer

Start date: February 2017
Phase: Phase 3
Study type: Interventional

In this study, we aim to investigate the value of circulating tumor DNA (ctDNA) analysis in the diagnosis, treatment, and surveillance of patients with surgically resectable colorectal cancer, by performing serial analysis of ctDNA, next-generation sequencing of surgical specimens, and observation of patients undergoing radical resection of the tumor with or without adjuvant chemo- and/or radiotherapy.